Yidu Tech Wins RMB7.39 Million AI Clinical Research Platform Bid in Tianjin

Meet Samuel – Your Personal Investing ProphetStart a conversation with TipRanks’ trusted, data-backed investment intelligence Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in secondsYidu Tech, Inc. ( (HK:2158) ) just unveiled an announcement. Yidu Tech Inc. announced that its affiliate Yidu Cloud (Beijing) Technology has won a bid to build an intelligent clinical research integrated platform for Tianjin Medical University Cancer Institute and Hospital, with the project valued at about RMB7.39 million. The contract underscores Yidu Tech’s growing role in applying AI-driven clinical decision support to major Chinese medical institutions, reinforcing its positioning as a key enabler of precision healthcare and potentially deepening its relationships within the cancer research and treatment ecosystem. By securing this oncology-focused project, Yidu Tech is expected to expand the deployment of its proprietary system-level intelligence in real-world hospital settings. The deal may help the company further validate its disease-understanding AI models, enhance its track record in large-scale clinical research infrastructure, and support its broader ambition to build a more resilient and inclusive healthcare future in China. More about Yidu Tech, Inc. Yidu Tech Inc. is a China-focused healthcare technology company that applies artificial intelligence to support the intelligent upgrading of the healthcare system. Its platforms and solutions target the full value chain across healthcare providers, pharmaceutical companies, insurers and patients, aiming to make precision medicine more accessible and to improve clinical decision-making efficiency. By modeling real-world disease progression and physicians’ decision logic, the company seeks to offer data-driven tools for diagnostics, treatment planning and public health management. Average Trading Volume: 7,234,807 Technical Sentiment Signal: Sell Current Market Cap: HK$5.77B For a thorough assessment of 2158 stock, go to TipRanks’ Stock Analysis page.